Cogent Biosciences Receives FDA Breakthrough Designation for Mastocytosis Treatment

Cogent Biosciences announces FDA Breakthrough Therapy Designation for bezuclastinib, a promising treatment for NonAdvanced Systemic Mastocytosis with NDA submission planned by year-end 2025.